Caption: Israeli cell therapy company, Pluristem Therapeutics is moving the science forward in Duchenne. Working with a leading Israeli DMD patient advocacy group, Association Duchenne Israel, Pluristem just concluded a preclinical study that demonstrated the
Credit: Pluristem Therapeutics